Answers are grounded in this paper and cite their sources.
A very recent work published in Advanced Science by our group reveals that 2′-deoxy-2′- β -fluoro-4′-azidocytidine (Azvudine, FNC), a clinical candidate originally developed for HIV treatment, has entered clinical trial in China for evaluating its efficacy and safety (ChiCTR2000029853), showing promise for treating novel coronavirus disease 2019 (COVID-19). 1 This work suggests that nucleoside-based antivirus agents could be repurposed for COVID-19 treatment.
No takes yet. Share an insight, caveat, or question.
Junbiao Chang (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: